+Search query
-Structure paper
Title | Cryo-EM structures of HCV E2 glycoprotein bound to neutralizing and non-neutralizing antibodies determined using bivalent Fabs as fiducial markers. |
---|---|
Journal, issue, pages | Commun Biol, Vol. 8, Issue 1, Page 825, Year 2025 |
Publish date | May 29, 2025 |
![]() | Salman Shahid / Sharanbasappa S Karade / S Saif Hasan / Rui Yin / Liqun Jiang / Yanxin Liu / Nathaniel Felbinger / Liudmila Kulakova / Eric A Toth / Zhen-Yong Keck / Steven K H Foung / Thomas R Fuerst / Brian G Pierce / Roy A Mariuzza / ![]() |
PubMed Abstract | Global elimination of hepatitis C virus (HCV) will require an effective cross-genotype vaccine. The HCV E2 envelope glycoprotein is the main target of neutralizing antibodies but also contains ...Global elimination of hepatitis C virus (HCV) will require an effective cross-genotype vaccine. The HCV E2 envelope glycoprotein is the main target of neutralizing antibodies but also contains epitopes that elicit non-neutralizing antibodies which may provide protection through Fc effector functions rather than direct neutralization. We determined cryo-EM structures of a broadly neutralizing antibody, a moderately neutralizing antibody, and a non-neutralizing antibody bound to E2 to resolutions of 3.8, 3.3, and 3.7 Å, respectively. Whereas the broadly neutralizing antibody targeted the front layer of E2 and the non-neutralizing antibody targeted the back layer, the moderately neutralizing antibody straddled both front and back layers, and thereby defined a new neutralizing epitope on E2. The small size of complexes between conventional (monovalent) Fabs and E2 (~110 kDa) presented a challenge for cryo-EM. Accordingly, we engineered bivalent versions of E2-specific Fabs that doubled the size of Fab-E2 complexes and conferred highly identifiable shapes to the complexes that facilitated particle selection and orientation for image processing. This study validates bivalent Fabs as new fiducial markers for cryo-EM analysis of small proteins such as HCV E2 and identifies a new target epitope for vaccine development. |
![]() | ![]() ![]() ![]() |
Methods | EM (single particle) / X-ray diffraction |
Resolution | 1.62 - 3.8 Å |
Structure data | EMDB-41245, PDB-8tgv: EMDB-41247, PDB-8tgz: EMDB-41275, PDB-8thz: EMDB-41703, PDB-8txq: EMDB-41774, PDB-8tzy: EMDB-42041, PDB-8u9y: ![]() PDB-8tfe: |
Chemicals | ![]() ChemComp-EDO: ![]() ChemComp-FLC: ![]() ChemComp-HOH: ![]() ChemComp-NAG: |
Source |
|
![]() | IMMUNE SYSTEM / Antibody / E2 glycoprotein / Fab fragment / ANTIVIRAL PROTEIN / HCV / E2 / Fab / antiviral / complex / vaccine target / ternary complex / VIRAL PROTEIN/IMMUNE SYSTEM / VIRAL PROTEIN-IMMUNE SYSTEM complex |